Report Highlights
The global market for neurology should grow from $33.3 billion in 2019 to $39.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.5% for the period of 2019-2024.
Report Includes
- 15 data tables and 22 additional tables
- An in-depth overview and industry analysis of the global market for neurology medicines
- Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Historical background on neurological disorders and therapeutics, growing prevalence of neurological disorders, increasing research and development activities regarding neurology research, and analysis of the factors influencing the market
- Quantitative analysis of the neurology therapeutics market covering Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases
- Discussion of various therapeutics used for treatment of different neurological disorders, along with coverage of novel pipeline, patent expiry of blockbuster drug and new drug approvals
- Reviews of the competitive landscape, key strategies adopted by market players, mergers and acquisitions details, pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage etc.
- Details company profile of leading participants within the neurology market including, AbbVie, Biogen, GlaxoSmithKline Plc, Johnson & Johnson, and Sun Pharmaceuticals Industries Ltd.
Report Scope
The scope of this report is broad and covers therapeutics used in treatment of neurological disorders.
The report highlights the current and future market potential of neurology medicines and provides a detailed analysis of the competitive environment, regulations, epidemiology of neurological diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.
The report details market shares of neurology based on different disease indication. Based on neurological disorders the market is segmented into Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases. Each diseases segment covers therapeutics and regional analysis.
The market of Parkinson Diseases covers anti-Parkinson’s drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into dopaminergic, enzyme inhibitors, dopamine agonists and other Anti-Parkinson’s medications. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of Alzheimer Diseases covers anti-Alzheimer drugs. the market is segmented based on mechanism of action of drugs and region. based on drug class the market is segmented into AChE inhibitors and NMDA antagonist. Based on region the market is segmented into North America, Europe, and Rest of the World.
The market of psychotic diseases covers antipsychotic drugs. The market is segmented into drug class and region. Based on drug, the market is segmented into D2 antagonists, D2/5HT2A antagonists, and D2 partial agonist. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of Epileptic Diseases covers Anti-Epileptic Drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into first generation drugs, second generation drugs, and third generation drugs. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of autism disorder covers autism disorder therapeutics. The market is segmented into drug based on labelled information and region. Based on drug class the market is segmented into ASD-labeled pharmaceuticals and Off-label pharmaceuticals. Based on region the market is segmented into North America, Europe, and Rest of the World.
The market of brain tumor covers brain tumor therapeutics. The market is segmented into therapy type and region. Based on therapy type, the market is segmented into chemotherapy and targeted therapy. Based on region, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.
For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets (HLC176E)
- Carbon Credits Market: Global Outlook (EGY200A)
- Drugs and Diagnostics for Hematological Disorders: Global Markets (PHM116C)
- Global Flame and Smoke Detectors Markets (MFG092A)
- Biodegradable Polymers: Global Markets and Technologies (PLS025K)
Related Reports
Neurology Devices: Global Markets
The global market for neurology devices is estimated to increase from $23.7 billion in 2023 to reach $31.7 billion by 2028, at a compound annual growth rate (CAGR) of 6.0% from 2023 through 2028.
Neurostimulation: Technologies and Global Markets
The global neurostimulation devices market should reach $11.7 billion by 2028 from $8.2 billion in 2023 at a compound annual growth rate (CAGR) of 7.4% for the forecast period of 2023 to 2028. Whereas the market was $7.7 billion in 2022 (base year).
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
The global market for Alzheimer's disease treatment should grow from $4.8 billion in 2020 to $6.3 billion by 2025 with a compound annual growth rate (CAGR) of 5.5% during the period of 2020-2025.
Theranostics: Global Markets
The global market for theranostics should grow from $80.4 billion in 2020 to $129.8 billion by 2025, at compound annual growth rate (CAGR) of 10.1% for the period of 2020-2025.
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More